# Lonza Group Ltd.

Lonza Group Ltd. is a CDMO / Pharmaceutical and Biotech Manufacturing based in Basel, Switzerland.

## Overview

- **Organization type:** CDMO / Pharmaceutical and Biotech Manufacturing
- **Headquarters:** Basel, Switzerland
- **Region:** Europe
- **Address:** Basel, Switzerland
- **Founded:** 1897
- **Assets under management:** Undisclosed
- **Website:** www.lonza.com
- **LinkedIn:** https://www.linkedin.com/company/lonza

## Regulatory record

- **Reports private funds:** No

## About

Lonza Group was founded in 1897 in Basel as a chemical manufacturer, later diversifying into specialty chemicals and eventually life sciences. Wolfgang Wienand took over as CEO in 2023 after serving as COO, inheriting a firm that had divested its specialty chemicals arm to focus entirely on pharma and biotech services. The firm's CDMO strategy covers drug substance and drug product manufacturing across small molecules, biologics, cell and gene therapies, and mRNA. Lonza operates over 20 manufacturing sites globally, including a flagship in Visp, Switzerland, and a newly expanded facility in Portsmouth, New Hampshire. Its clients range from emerging biotechs to top-20 pharma companies. Lonza employs roughly 18,000 people worldwide. In 2024, the firm broke ground on a new large-scale biologics plant in Stein, Switzerland, expected to cost CHF 500M (per company press release, 2024). Adjacent operations include a bioscience division that supplies research tools and custom media. Lonza's structural differentiator is its scale and breadth as a pure-play CDMO — one of the few contract manufacturers that can handle every modality from discovery through commercial supply. Its 127-year history gives it deep regulatory expertise, but it also faces the structural risk of client dependence and capital intensity.

## Sectors

- Healthcare Services
- Industrial Tech
- Infrastructure

## Offices

- Portsmouth, NH, USA
- Slough, UK
- Singapore
- Shanghai, China
- Tokyo, Japan
- Walkersville, MD, USA

## People

- Wolfgang Wienand — CEO
- Philippe Deecke — CFO

## Questions

### Who makes investment decisions at Lonza Group?

Lonza Group operates as a publicly traded company, not a family office. Strategic allocation and capital deployment are managed by the executive committee under CEO Wolfgang Wienand, with oversight from the board of directors. Major investments in capacity or R&D are announced via press releases.

### Does Lonza Group invest in external funds or direct deals?

Lonza Group does not function as an investment firm; it is a contract manufacturer. Its capital expenditures go toward building and expanding manufacturing capacity, not into external funds or portfolio companies.

### What sectors does Lonza Group focus on?

Lonza Group focuses exclusively on life sciences, providing CDMO services to the pharmaceutical and biotechnology industries. Its core segments are biologics, small molecules, cell and gene therapy, and mRNA.

### Where does Lonza Group operate geographically?

Lonza Group has manufacturing sites in Switzerland, the United States, the United Kingdom, Singapore, China, and Japan. Its headquarters are in Basel, Switzerland.

### How has Lonza Group's business model evolved?

Founded as a chemical company in 1897, Lonza Group transitioned to specialty chemicals and later into life sciences. In the 2020s, it divested its specialty chemicals business to become a pure-play CDMO, now ranking among the global leaders in contract drug manufacturing.

## Related profiles

- [Cauris](https://altss.com/profile/cauris)
- [NEC Corporation](https://altss.com/profile/nec-corporation)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/lonza-group-ltd

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology